Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ezekowitz

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Circulation|September 11, 2013
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy studyEloi Marijon, Jean-Yves Le Heuzey, Stuart Connolly, et al.
Circulation|August 27, 2014
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study"Eloi Marijon, Jean-Yves Le Heuzey, Stuart Connolly, et al.
Heart (British Cardiac Society)|November 11, 2015
Dabigatran etexilate and reduction in serum apolipoprotein BPhilip Joseph, Guillaume Pare, Lars Wallentin, et al.
The American Journal of Cardiology|March 24, 2021
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)Dominic Millenaar, Helmut Schumacher, Martina Brueckmann, et al.
Circulation|April 18, 2018
Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart AssociationLin Y Chen, Mina K Chung, Larry A Allen, et al.
Digestive Diseases and Sciences|March 28, 2018
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or DabigatranJennifer M Kolb, Kathryn Friedman Flack, Prapti Chatterjee-Murphy, et al.
Chest|July 24, 2008
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Richard C Becker, Thomas W Meade, Peter B Berger, et al.
Circulation|September 25, 2002
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudyDavid D Waters, Gregory G Schwartz, Anders G Olsson, et al.
Circulation|December 29, 2012
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialAntonio L Dans, Stuart J Connolly, Lars Wallentin, et al.
European Heart Journal|May 10, 2020
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trialMichael Böhm, Martina Brueckmann, John W Eikelboom, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Circulation|September 11, 2013
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy studyEloi Marijon, Jean-Yves Le Heuzey, Stuart Connolly, et al.
Circulation|August 27, 2014
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study"Eloi Marijon, Jean-Yves Le Heuzey, Stuart Connolly, et al.
Heart (British Cardiac Society)|November 11, 2015
Dabigatran etexilate and reduction in serum apolipoprotein BPhilip Joseph, Guillaume Pare, Lars Wallentin, et al.
The American Journal of Cardiology|March 24, 2021
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)Dominic Millenaar, Helmut Schumacher, Martina Brueckmann, et al.
Circulation|April 18, 2018
Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart AssociationLin Y Chen, Mina K Chung, Larry A Allen, et al.
Digestive Diseases and Sciences|March 28, 2018
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or DabigatranJennifer M Kolb, Kathryn Friedman Flack, Prapti Chatterjee-Murphy, et al.
Chest|July 24, 2008
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Richard C Becker, Thomas W Meade, Peter B Berger, et al.
Circulation|September 25, 2002
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudyDavid D Waters, Gregory G Schwartz, Anders G Olsson, et al.
Circulation|December 29, 2012
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialAntonio L Dans, Stuart J Connolly, Lars Wallentin, et al.
European Heart Journal|May 10, 2020
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trialMichael Böhm, Martina Brueckmann, John W Eikelboom, et al.
Pageof 5